

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Zacharia Cheruvallath et al.

Serial No.: 11/683,955

Filed: March 8, 2007

For: GLUCOKINASE ACTIVATORS

Group Art Unit: 1624

Examiner: Not Yet Assigned

Compared to the property of the property

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449, and copies of the non-US patent references are included for the Examiner's convenience.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicants as such.

CERTIFICATE OF TRANSMISSION

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being delivered via hand delivery to the Commissioner for Patents, Randolph Building, 401 Dulany Street, Alexandria, Virginia 22314.

Name of Person Delivering Paper

Signature of Person Delivering Paper

Date of Deposit

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

\boxtimes	This II	OS is believed to be timely in that it is being submitted under 37 CFR §
	•	is (1) within three months of the filing date of the application, which is not a
		osecution application filed under § 1.53(d); or (2) within three months of
		ational stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a
		tion on the merits; or (4) before the mailing of a first Office action after filing
a requ	uest for	continued examination under § 1.114. Thus, no fee is required.
		However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR §1.17(p) to the deposit account referenced below.
		However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.
	action	OS is being submitted under 37 CFR \S 1.97(c), that is after mailing of a first on the merits, but before a Final Action under 37 CFR \S 1.113 or a Notice
of Allo	wance	under 37 CFR § 1.311.
		The fee due under 37 CFR § 1.17(p) is submitted herewith.
		A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.
payme	37 CFF ent of th	OS is being submitted under 37 CFR § 1.97(d), that is after a Final Action R § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before he issue fee. A statement under 37 CFR § 1.97(e) is included below. The r 37 CFR § 1.17(p) is submitted herewith.
		STATEMENT UNDER 37 CFR § 1.97(e):
	Each i	tem contained in this IDS was first cited in any communication from a
foreigr	n paten	t office in a counterpart foreign application not more than three months
		ing of this IDS.
	No iter	m contained in this IDS was cited in a communication from a foreign patent
office		Interpart foreign application, and, to the knowledge of the person signing

this statement after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.

	Payment and/or Authorization to Charge Fees:							
	A check in the amount of is enclosed for the above fee(s).							
	Please charge to Deposit Account No. 50-2256 for the above fee(s).							
	Although Applicants do not believe any fees are required, the Commissioner is prized to charge any fees required by the filing of these papers to Takeda's Deposit unt No. 50-2256.							
	Respectfully submitted,							
	TAKEDA SAN DIEGO, INC.							
Dated	d: April 24, 2007 By: Mitchell R. Brustein Reg. No. 38,394							

Customer No. **32793**Takeda San Diego, Inc.
10410 Science Center Drive
San Diego, CA 92121

Tel: (858) 622-8528 Fax: (858) 550-0992 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Reduction Act of 695, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form

Under the Pap

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 7

Complete if Known						
Application Number	11/683,955					
Filing Date	03/08/2007					
First Named Inventor	Zacharia Cheruvallath					
Group Art Unit	1624					
Examiner Name	Not Yet Assigned					
Attorney Docket Number	GK-5006-U					

			U.S. PATENT I	DOCUMENTS	
Examiner Initials *	Cite No.1	Document Number Number - Kind Code ² (if known)	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US 4,900,423	2/13/1990	lida Takeaki et al.	rigures Appear
	AB	US 4,959,212	9/25/1990	Stancesco Alexandra et al.	
	AC	US 5,239,080	8/24/1993	Sohda Takashi et al.	
	AD	US 5,424,204	6/13/1995	Aoyama Norihito et al.	
	AE	US05501965	3/26/1996	Iwata Ken et al.	
-	AF	US 5,541,060	7/30/1996	Bell Graeme I. et al.	
	AG	US 5,854,067	12/29/1998	Newgard Christopher B. et al.	
	AH	US 20010039344 A1	11/8/2001	Bizzarro Fred Thomas et al.	
	Ai	US 6,320,050	11/20/2001	Bizzarro Fred Thomas et al.	
	AJ	US 20010051731 A1	12/13/2001	Bizzarro Fred T. et al.	
	AK	US 20010053851 A1	12/20/2001	Mahaney Paige E.	
	AL	US 20010056191 A1	12/27/2001	Goodnow Robert A. JR. et al.	
	AM	US 20020002190 A1	1/3/2002	Corbett Wendy L. et al.	
	AN	US 6,353,111	3/5/2002	Corbett Wendy Lea et al.	
	AO	US 20020032330 A1	3/14/2002	Nomura Yutaka et al.	
	AP	US 20020035266 A1	3/21/2002	Sidduri Achyutharao	
	AQ	US 20020035267 A1	3/21/2002	Sidduri Achyutharao	
	AR	US 6,369,232	4/9/2002	Sidduri Achyutharao et al.	
	AS	US 20020042512 A1	4/11/2002	Kester Robert F. et al.	
	AT	US 6,384,220	5/7/2002	Corbett Wendy Lea et al.	
	AU	US 6,388,071	5/14/2002	Mahaney Paige Erin	
,	AV	US 6,388,088	5/14/2002	Sidduri Achyutharao	
	AW	US 20020065239 A1	5/30/2002	Caplan Shari L. et al.	
	AX	US 20020065275 A1	5/30/2002	Sidduri Achyutharao	
	AY	US 20020082260 A1	6/27/2002	Guertin Kevin Richard	
	AZ	US 20020103199 A1	8/1/2002	Corbett Wendy L. et al.	
	BA	US 20020103241 A1	8/1/2002	Corbett Wendy L. et al.	
	BB	US 20020107396 A1	8/8/2002	Corbett Wendy L. et al.	
	ВС	US 6,433,188	8/13/2002	Corbett Wendy Lea et al.	
	BD	US 20020110863 A1	8/15/2002	Kawase Shido et al.	
	BE	US 20020111372 A1	8/15/2002	Corbett Wendy L. et al.	
	BF	US 6,441,180	8/27/2002	Sidduri Achyutharao	
	BG	US 6,441,184	8/27/2002	Corbett Wendy Lea et al.	
	вн	US 6,448,399	9/10/2002	Corbett Wendy Lea et al.	

	, , , , , , , , , , , , , , , , , , , 		
Examiner		Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number 11/683.955 INFORMATION DISCLOSURE Filing Date 03/08/2007 STATEMENT BY APPLICANT First Named Inventor Zacharia Cheruvallath Group Art Unit 1624 (use as many sheets as necessary) **Examiner Name** Not Yet Assigned Sheet GK-5006-U Attorney Docket Number

ВІ	US 6,482,951	11/19/2002	Guertin Kevin Richard	
BJ	US 6,486,184	11/26/2002	Kester Robert Francis et al.	
ВК	US 6,486,380	11/26/2002	Epstein Paul N.	
BL	US 6,489,485	12/3/2002	Bizzarro Fred Thomas et al.	
 ВМ	US 20020198200 A1	12/26/2002	Kester Robert F. et al.	
BN	US 6,503,887	1/7/2003	During Matthew J. et al.	
во	US 6,528,543	3/4/2003	Bizzarro Fred Thomas et al.	
 BP	US 20030060625 A1	3/27/2003	Bizzarro Fred Thomas et al.	
BQ	US 6,545,155	4/8/2003	Corbett Wendy Lea et al.	
BR	US 20030082700 A1	5/1/2003	Baker Kevin P. et al.	
BŞ	US 20030082706 A1	5/1/2003	Baker Kevin P. et al.	
BT	US 20030082728 A1	5/1/2003	Baker Kevin P. et al.	
BU	US 20030092106 A1	5/15/2003	Baker Kevin P. et al.	
BV	US 6,566,109	5/20/2003	Kawase Shido et al.	
BW	US 20030096964 A1	5/22/2003	Baker Kevin P. et al.	
BX	US 20030096967 A1	5/22/2003	Baker Kevin P. et al.	
BY	US 20030100725 A1	5/29/2003	Baker Kevin P. et al.	
 BZ	US 20030100730 A1	5/29/2003	Baker Kevin P. et al.	
CA	US 6,583,288	6/24/2003	Goodnow Jr. Robert Alan et al.	
 CB	US 20030129691 A1	7/10/2003	Baker Kevin P. et al.	
 CC	US 20030129694 A1	7/10/2003	Baker Kevin P. et al.	
 CD	US 20030138416 A1	7/24/2003	Lau Jesper.	
 CE	US 6,608,218	8/19/2003	Kester Robert Francis et al.	
CF	US 6,610,846	8/26/2003	Bizzarro Fred Thomas et al.	
 CG	US 20030171411 A1	9/11/2003	Kodra Janos Tibor et al.	
СН	US 20030181653 A1	9/25/2003	Eaton Dan L. et al.	
CI	US 20030181657 A1	9/25/2003	Eaton Dan L. et al.	
CJ	US 20030181684 A1	9/25/2003	Eaton Dan L. et al.	
CK	US 20030181686 A1	9/25/2003	Eaton Dan L. et al.	
 CL	US 20030181707 A1	9/25/2003	Eaton Dan L. et al.	
СМ	US 20030190716 A1	10/9/2003	Eaton Dan L. et al.	
CN	US 20030194779 A1	10/16/2003	Baker Kevin P. et al.	
 CO	US 20030194793 A1	10/16/2003	Baker Kevin P. et al.	
 CP	US 20030199025 A1	10/23/2003	Baker Kevin P. et al.	
CQ	US 20030199027 A1	10/23/2003	Baker Kevin P. et al.	
CR	US 20030207385 A1	11/6/2003	Baker Kevin P. et al.	
CS	US 20030219887 A1	11/27/2003	Corbett Wendy Lea et al.	

$\overline{}$	 	
Examiner	Date	
Signature	Considered	
(3	00	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitut	e for form 1449A/PTO)		Complete if Known		
				Application Number	11/683,955	
INFC	PRMATION	DIS	CLOSURE	Filing Date	03/08/2007	
STA	TEMENT BY	Y A	PPLICANT	First Named Inventor	Zacharia Cheruvallath	
				Group Art Unit	1624	
	(use as many she	ets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	3	of	7	Attorney Docket Number	GK-5006-U	

<u> </u>	CT	US 20030225283 A1	12/4/2003	Corbett Woody Loo et al
1				Corbett Wendy Lea et al. Goodnow Robert Alan JR. et
	CU	US 20030225286 A1	12/4/2003	al.
	CV	US 20030232370 A1	12/18/2003	Trifiro Mark A.
	CW	US 20040009492 A1	1/15/2004	Kim Mi-Kyung et al.
	CX	US 20040014968 A1	1/22/2004	Bizzarro Fred Thomas et al.
	CY	US 20040039164 A1	2/26/2004	Baker Kevin P. et al.
	CZ	US 20040043457 A1	3/4/2004	Schumacher Silke et al.
	DA	US 20040044179 A1	3/4/2004	Baker Kevin P. et al.
	DB	US 20040044180 A1	3/4/2004	Baker Kevin P. et al.
	DC	US 20040048332 A1	3/11/2004	Baker Kevin P. et al.
	DD	US 20040048333 A1	3/11/2004	Baker Kevin P. et al.
	DE	US 20040048334 A1	3/11/2004	Baker Kevin P. et al.
	DF	US 20040048335 A1	3/11/2004	Baker Kevin P. et al.
	DG	US 20040053245 A1	3/18/2004	Tang Y. Tom et al.
	DH	US 20040053397 A1	3/18/2004	Iwamoto Keiji et al.
	DI	US 20040058398 A1	3/25/2004	Sarvetnick Nora et al.
	DJ	US 20040063156 A1	4/1/2004	Rademacher Thomas William et al.
	DK	US 20040067222 A1	4/8/2004	Walker Brian Robert et al.
	DL	US 20040067939 A1	4/8/2004	Corbett Wendy Lea et al.
	DM	US 20040081981 A1	4/29/2004	Egashira Toru et al.
	DN	US 20040086875 A1	5/6/2004	Agee Michele L. et al.
	DO	US 20040086954 A1	5/6/2004	Goueli Said et al.
	DP	US 20040091959 A1	5/13/2004	Baker Kevin P. et al.
	DQ	US 20040091972 A1	5/13/2004	Baker Kevin P. et al.
	DR	US 20040106555 A1	6/3/2004	German Michael S.
	DS	US 20040108226 A1	6/10/2004	Polychronakos Constantin et al.
	DT	US 20040110246 A1	6/10/2004	Ebinuma Hiroyuki et al.
	DU	US 20040116423 A1	6/17/2004	Nivorozhkin Alex et al.
	DV	US 20040122235 A1	6/24/2004	Polisetti Dharma Rao et al.
	DW	US 20040126839 A1	7/1/2004	Baker Kevin P. et al.
	DX	US 20040127400 A1	7/1/2004	Smith Daniel J. et al.
	DY	US 20040128707 A1	7/1/2004	Ishino Fumitoshi et al.
	DZ	US 20040132679 A1	7/8/2004	Chan Lawrence et al.
	EA	US 20040137517 A1	7/15/2004	Andrews John Leon et al.
	EB	US 20040142373 A1	7/22/2004	Gonye Gregory E. et al.
	EC	US 20040142901 A1	7/22/2004	German Michael S.

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection sestimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitut	e for form 1449A/PTC)		Complete if Known		
				Application Number	11/683,955	
INFC	RMATION	DIS	CLOSURE	Filing Date	03/08/2007	
STA	TEMENT B	Y A	PPLICANT	First Named Inventor	Zacharia Cheruvallath	
				Group Art Unit	1624	
	(use as many she	ets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	4	of	7	Attorney Docket Number	GK-5006-U	

 		 	
ED	US 20040143110 A1	7/22/2004	Krolewski Andrzej S. et al.
EE	US 20040143854 A1	7/22/2004	Klebi Bert et al.
EF	US 20040146922 A1	7/29/2004	Gonye Gregory E. et al.
EG	US 20040147017 A1	7/29/2004	Ashkenazi Avi et al.
EH	US 20040147725 A1	7/29/2004	Chuntharapai Anan et al.
EI	US 20040147748 A1	7/29/2004	Chen Shaoqing et al.
EJ	US 6,784,298	8/31/2004	Goodnow Jr. Robert Alan et al.
EK	US 20040175740 A1	9/9/2004	Brennan Miles B. et al.
EL	US 20040180808 A1	9/16/2004	NYE STEVEN H. et al.
EM	US 20040180845 A1	9/16/2004	Newgard Christopher B. et al.
EN	US 20040181067 A1	9/16/2004	Fyfe Matthew Colin Thor et al.
EO	US 20040185531 A1	9/23/2004	Ashkenazi Avi et al.
EP	US 20040185548 A1	9/23/2004	Ji Qun-Sheng
EQ	US 20040186290 A1	9/23/2004	Fyfe Matthew Colin Thor et al.
ER	US 20040191901 A1	9/30/2004	Assady Suheir et al.
ES	US 20040197792 A1	10/7/2004	Whyte David et al.
ET	US 20040198969 A1	10/7/2004	Baldwin Daryl T. et al.
EU	US 20040209797 A1	10/21/2004	Karas Michael
EV	US 20040213769 A1	10/28/2004	Ferber Sarah
EW	US 20040214187 A1	10/28/2004	Van Der Vuurst De Vries Anne-Renee et al.
EX	US 20040214265 A1	10/28/2004	Baker Kevin P. et al.
EY	US 20040214266 A1	10/28/2004	Baker Kevin P. et al.
EZ	US 20040214267 A1	10/28/2004	Baker Kevin P. et al.
FA	US 20040214269 A1	10/28/2004	Baker Kevin P. et al.
FB	US 20040214868 A1	10/28/2004	Hayter Barry Raymond et al.
FC	US 20040223964 A1	11/11/2004	Ashkenazi Avi J. et al.
FD	US 20050009129 A1	1/13/2005	Rizzo Mark A.et al.
FE	US 20050031605 A1	2/10/2005	Bunn Howard F. et al.
FF	US 20050032711 A1	2/10/2005	Patel Mona et al.
FG	US 20050032712 A1	2/10/2005	Urbanski Maud
FH	US 20050043391 A1	2/24/2005	Fong Benson M. et al.
FI	US 20050049310 A1	3/3/2005	Mjalli Adnan M.M. et al.
FJ	US 20050054715 A1	3/10/2005	Hayter Barry Raymond et al.
FK	US 6,881,844	4/19/2005	Corbett Wendy Lea et al.

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute	Substitute for form 1449A/PTO				Complete if Known
				Application Number	11/683,955
INFC	RMATION	DIS	CLOSURE	Filing Date	03/08/2007
STA	STATEMENT BY APPLICANT			First Named Inventor	Zacharia Cheruvallath
				Group Art Unit	1624
	(use as many she	ets as	necessary)	Examiner Name	Not Yet Assigned
Sheet	5	of	7	Attorney Docket Number	GK-5006-U

		FOREIGN PA	ATENT DOCL	JMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	FL	WO 00/053756 A2 & A3	9/14/2000	GENENTECH, INC.		
	FM	WO 00/058293 A2 & A3	10/5/2000	F. HOFFMANN-LA ROCHE AG		
	FN	WO 00/144216 A1	6/21/2001	F. HOFFMANN-LA ROCHE AG		
	FO	WO 00/183465 A2 & A3	11/8/2001	F. HOFFMANN-LA ROCHE AG		
	FP	WO 00/183478 A2 & A3	11/8/2001	F. HOFFMANN-LA ROCHE AG		
	FQ	WO 00/185706 A1	11/15/2001	F. HOFFMANN-LA ROCHE AG		
	FR	WO 00/185707 A1	11/15/2001	F. HOFFMANN-LA ROCHE AG		
	FS	WO 00/188088 A2 & A3	11/22/2001	HYSEQ, INC.		
	FT	WO 00/190325 A2 & A3	11/29/2001	MILLENNIUM PHARMACEUTICALS, INC.		
	FU	WO 00/192523 A2 & A3	12/6/2001	CURAGEN CORPORATION		
	FV	WO 00/198454 A2	12/27/2001	GERMAN HUMAN GENOME PROJECT		
	FW	WO 00/200691A2 & A3	1/3/2002	CURAGEN CORPORATION		
	FX	WO 00/206339 A2 & A3	1/24/2002	CURAGEN CORPORATION		
	FY	WO 00/208209 A1	1/31/2002	F. HOFFMANN-LA ROCHE AG		
	FZ	WO 00/208277 A2 & A3	1/31/2002	ELI LILLY AND COMPANY		
	GA	WO 00/208288 A2 & A3	1/31/2002	GENENTECH, INC.		
	GB	WO 00/208289 A2 & A3	1/31/2002	CURAGEN CORPORATION		
	GC	WO 00/214312 A1	2/21/2002	F. HOFFMANN-LA ROCHE AG		
	GD	WO 00/214358 A2 & A3	2/21/2002	ELI LILLY AND COMPANY		
	GE	WO 00/214500 A2 & A3	2/21/2002	HYSEQ INC.		
	GF	WO 00/216578 A2 & A3	2/28/2002	ELI LILLY AND COMPANY		
	GG	WO 00/216599 A2 & A3	2/28/2002	COR THERAPEUTICS, INC.		
	GH	WO 00/218409 A1	3/7/2002	ISIS PHARMACEUTICALS, INC.		
	GI	WO 00/218621 A2	3/7/2002	WAKE FOREST UNIVERSITY		
	GJ	WO 00/226801 A2 & A3	4/4/2002	ELI LILLY AND COMPANY		
	GK	WO 00/232939 A2 & A3	4/25/2002	ELI LILLY AND COMPANY		
	GL	WO 00/246173 A1	6/13/2002	F. HOFFMANN-LA ROCHE AG		
	GM	WO 00/246409 A2 & A3	6/13/2002	CURAGEN CORPORATION		
	GN	WO 00/248106 A2 & A3	6/20/2002	F. HOFFMANN-LA-ROCHE AG		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute	Substitute for form 1449A/PTO				Complete if Known
				Application Number	11/683,955
INFC	RMATION	DIS	CLOSURE	Filing Date	03/08/2007
STA	TEMENT B'	Υ ΑΙ	PPLICANT	First Named Inventor	Zacharia Cheruvallath
				Group Art Unit	1624
	(use as many she	ets as	necessary)	Examiner Name	Not Yet Assigned
Sheet	6	of	7	Attorney Docket Number	GK-5006-U

	GO	WO 00/248361 A2 & A3	6/20/2002	ELI LILLY AND COMPANY	
	GP	WO 00/249423 A1	6/27/2002	UNIVERSITAT AUTONOMA DE BARCELONA	
	GQ	WO 00/250277A2 & A3	6/27/2002	CURAGEN CORPORATION	
	GR	WO 02/055704 A2 & A3	7/18/2002	CURAGEN CORPORATION	
(GS	WO 02/055705 A2 & A3	7/18/2002	CURAGEN CORPORATION	
	GT	WO 02/057450 A2 & A3	7/25/2002	CURAGEN CORPORATION	
	GU	WO 02/057453 A2 & A3	7/25/2002	CURAGEN CORPORATION	
	GV	WO 02/059315 A2 & A3	8/1/2002	CURAGEN CORPORATION	
G	3W	WO 02/064791 A2 & A3	8/22/2002	CURAGEN CORPORATION	
	GX	WO 02/065985 A2 & A3	8/29/2002	NOBEX CORPORATION	
	GY	WO 02/068649 A3	9/6/2002	CURAGEN CORPORATION	
	GZ	WO 02/068680 A2 & A3	9/6/2002	MITOKOR	
	HA	WO 02/070539 A2 & A3	9/12/2002	HYSEQ, INC.	
	HB	WO 02/072757 A2 & A3	9/19/2002	CURAGEN CORPORATION	
	нс	WO 02/072875 A1	9/19/2002	CHINESE UNIVERSITY OF HONG KONG	
ŀ	HD	WO 02/081498 A2 & A3	10/17/2002	CURAGEN CORPORATION	
1	HE	WO 02/081517 A2 & A3	10/17/2002	CURAGEN CORPORATION	
	HF	WO 02/093127 A2 & A3	11/21/2002	TAKEDA CHEMICAL INDUSTRIES, LTD.	
H	HG	WO 02/097434 A1	12/5/2002	SYDDANSK UNIVERSITET	
1	HH	WO 02/098355 A2 & A3	12/12/2002	MA Yuanhong et al.	
	HI	WO 02/101074 A2 & A3	12/19/2002	BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.	
	HJ	WO 03/000262 A1	1/3/2003	ASTRAZENECA AB	
	HK	WO 03/000267 A1	1/3/2003	ASTRAZENECA AB	
	HL	WO 03/015774 A1	2/27/2003	ASTRAZENECA AB	
F	НМ	WO 03/047626 A1	6/12/2003	NOVO NORDISK A/S	
<u> </u>	HN	WO 03/054198 A1	7/3/2003	DEGUSSA AG	
h	НО	WO 03/055482 A1	7/10/2003	NOVO NORDISK A/S	
I	HP	WO 03/080585 A1	10/2/2003	BANYU PHARMACEUTICAL CO., LTD.	
ŀ	HQ	WO 03/095438 A1	11/20/2003	F. HOFFMANN-LA ROCHE AG	
<u> </u>	HR	WO 03/097824 A1	11/27/2003	BANYU PHARMACEUTICAL CO., LTD.	
1	HS	WO 03/102161 A2 & A3	12/11/2003	METABOLEX, INC.	
	HT	WO 03/102163 A2	12/11/2003	METABOLEX, INC.	
1	HU	WO 03/101284 A2 & A3	12/11/2003	METABOLEX, INC.	
	HV _.	WO 03/103597 A2 & A3	12/18/2003	METABOLEX, INC	
	HW	WO 03/103601 A2 & A3	12/18/2003	METABOLEX, INC.	

_		
Examiner	Date	1
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 144	Substitute for form 1449A/PTO		Complete if Known	
		Application Number	11/683,955	
INFORMAT	ION DISCLOSURI	Filing Date	03/08/2007	
STATEMEN	IT BY APPLICAN	First Named Inventor	Zacharia Cheruvallath	
		Group Art Unit	1624	
, (use as ma	nny sheets as necessary)	Examiner Name	Not Yet Assigned	
Sheet 7	of 7	Attorney Docket Number	GK-5006-U	

,	HX	WO 03/105879 A1	12/24/2003	METABOLEX, INC.	
	HY	WO 04/002481 A1	1/8/2004	NOVO NORDISK A/S	
	HZ	WO 04/031179 A1	4/15/2004	F. HOFFMANN-LA ROCHE AG	
	IA	WO 04/039954 A2 & A3	5/13/2004	JOSLIN DIABETES CENTER, INC.	
	IB	WO 04/046139 A1	6/3/2004	ASTRAZENECA AB	
	IC	WO 04/045614 A1	6/3/2004	ASTRAZENECA AB	
	ID	WO 04/050645 A1	6/17/2004	NOVARTIS AG	
	IE	WO 04/052869 A1	6/24/2004	F. HOFFMANN-LA ROCHE AG	
	IF	WO 04/063179 A1	7/29/2004	ELI LILLY AND COMPANY	
	IG	WO 04/063194 A1	7/29/2004	ELI LILLY AND COMPANY	
	IH	WO 04/072031 A2 & A3	8/26/2004	OSI PHARMACEUTICALS, INC.	
	- 11	WO 04/072066 A1	8/26/2004	OSI PHARMACEUTICALS, INC.	
	IJ	WO 04/076420 A1	9/10/2004	BANYU PHARMACEUTICAL CO., LTD.	
	IK	WO 04/081001 A1	9/23/2004	BANYU PHARMACEUTICAL CO., LTD.	
	IL	WO 04/099246 A2	11/18/2004	NOVO NORDISK A/S	
	IM	WO 04/100944 A1	11/25/2004	SYNTHON B.V.	
	IN	WO 04/101505 A1	11/25/2004	NOVO NORDISK A/S	
	10	WO 05/030032 A2 & A3	4/7/2005	REGENTS OF UNIVERSITY OF COLORADO	
	IP	WO 05/054200 A1	6/16/2005	ASTRAZENECA AB	
	IQ	WO 05/054233 A1	6/16/2005	ASTRAZENECA AB	

	· · · · · · · · · · · · · · · · · · ·	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2

Examiner	1	Date	
Signature		Considered	1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.